• Plus Therapeutics signed a regional coverage agreement with Medical Mutual for the CNSide cerebrospinal fluid tumor cell enumeration assay, effective July 1, 2026.
• Coverage spans about 1.2 million members across Ohio, Kentucky.
• Total contracted coverage for the CNSide CSF assay rose to about 127 million people.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Plus Therapeutics Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202607210730PRIMZONEFULLFEED9764974) on July 21, 2026, and is solely responsible for the information contained therein.